Panagora Asset Management Inc. Acquires 210,032 Shares of AngioDynamics, Inc. $ANGO

Key Points

• Panagora Asset Management Inc. significantly increased its holdings in AngioDynamics, Inc., acquiring an additional 210,032 shares, raising its position by 249.5% during the first quarter.
• AngioDynamics reported earnings per share of ($0.03) for the latest quarter, surpassing analyst expectations, with a revenue increase of 13.0% year-over-year.
• Multiple analysts have upgraded AngioDynamics to a buy rating, with a consensus target price set at $19.00, reflecting positive sentiment in the market.

Panagora Asset Management Inc. raised its holdings in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 249.5% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 294,206 shares of the medical instruments supplier's stock after acquiring an additional 210,032 shares during the quarter. Panagora Asset Management Inc. owned approximately 0.72% of AngioDynamics worth $2,763,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. ProShare Advisors LLC acquired a new position in AngioDynamics in the 4th quarter valued at approximately $100,000. Graham Capital Management L.P. acquired a new position in AngioDynamics in the 4th quarter valued at approximately $106,000. Cerity Partners LLC increased its position in AngioDynamics by 22.0% in the 1st quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier's stock valued at $121,000 after acquiring an additional 2,333 shares during the period. GAMMA Investing LLC increased its position in AngioDynamics by 1,281.4% in the 1st quarter. GAMMA Investing LLC now owns 13,897 shares of the medical instruments supplier's stock valued at $130,000 after acquiring an additional 12,891 shares during the period. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in AngioDynamics in the 1st quarter valued at approximately $139,000. 89.43% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Wall Street Zen upgraded shares of AngioDynamics from a "hold" rating to a "buy" rating in a research report on Saturday, August 16th. Lake Street Capital assumed coverage on shares of AngioDynamics in a research report on Wednesday, July 16th. They set a "buy" rating and a $24.00 price objective for the company. HC Wainwright reiterated a "buy" rating and set a $16.00 price objective on shares of AngioDynamics in a research report on Wednesday, July 16th. Finally, Canaccord Genuity Group increased their price objective on shares of AngioDynamics from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Wednesday, July 16th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, AngioDynamics presently has an average rating of "Buy" and an average price target of $19.00.

AngioDynamics Trading Up 0.3%

NASDAQ ANGO traded up $0.03 on Monday, hitting $10.76. 86,052 shares of the company were exchanged, compared to its average volume of 611,899. The company has a market cap of $437.18 million, a PE ratio of -12.97 and a beta of 0.64. AngioDynamics, Inc. has a 12 month low of $5.83 and a 12 month high of $13.50. The stock has a fifty day moving average of $9.28 and a 200-day moving average of $9.55.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.09. The business had revenue of $80.16 million for the quarter, compared to analyst estimates of $74.26 million. AngioDynamics had a negative net margin of 11.62% and a negative return on equity of 3.20%. AngioDynamics's revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.06) earnings per share. AngioDynamics has set its FY 2026 guidance at -0.350--0.250 EPS. On average, analysts expect that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.